Characterization of the serum levels of Meteorin-like in patients with inflammatory bowel disease and its association with inflammatory cytokines.
Adiponectin
Crohn’s disease
Inflammatory bowel disease
Interleukin
Meteorin-like
Tumor necrosis factor
Ulcerative colitis
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
30 Oct 2020
30 Oct 2020
Historique:
received:
02
07
2020
accepted:
19
10
2020
entrez:
31
10
2020
pubmed:
1
11
2020
medline:
13
8
2021
Statut:
epublish
Résumé
Meteorin-like (Metrnl) is an adipokine with insulin sensitizing and anti-inflammatory properties that has been discovered recently. The relation among Metrnl, Inflammatory Bowel Disease (IBD), and obesity has been unexplored yet. The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn's disease (CD) patients who were diagnosed by pathological examination. In all participants, serum levels of adiponectin, Metrnl, interleukin (IL)-6, and Tumor necrosis factor (TNF-α) were measured using ELISA kits. Metrnl concentration was considerably lower in both UC (85.25 ± 36.55 pg/mL) and CD (76.93 ± 27.92 pg/mL) patients in comparison to control (107.52 ± 35.33 pg/mL). In addition, it was seen that both patient groups have a decreased level of adiponectin compared to the controls. Besides that, the level of IL-6 and TNF-α were significantly greater in the patient groups. Moreover, the result showed that the level of Metrnl is inversely correlated with body mass index (BMI) in the controls and the patients. Metrnl levels are also inversely associated with IL-6, and TNF-α in both of the patient groups. The current study is the first one reporting the decreased levels of Metrnl in serum among patients with IBD, which is inversely related with BMI, TNF-α, and IL-6. These results suggested a possible relation of Metrnl with the pathogenesis of IBD, particularly through inflammatory process, although further studies are warranted to dissect the possible mechanism.
Sections du résumé
BACKGROUND
BACKGROUND
Meteorin-like (Metrnl) is an adipokine with insulin sensitizing and anti-inflammatory properties that has been discovered recently. The relation among Metrnl, Inflammatory Bowel Disease (IBD), and obesity has been unexplored yet.
METHODS
METHODS
The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn's disease (CD) patients who were diagnosed by pathological examination. In all participants, serum levels of adiponectin, Metrnl, interleukin (IL)-6, and Tumor necrosis factor (TNF-α) were measured using ELISA kits.
RESULTS
RESULTS
Metrnl concentration was considerably lower in both UC (85.25 ± 36.55 pg/mL) and CD (76.93 ± 27.92 pg/mL) patients in comparison to control (107.52 ± 35.33 pg/mL). In addition, it was seen that both patient groups have a decreased level of adiponectin compared to the controls. Besides that, the level of IL-6 and TNF-α were significantly greater in the patient groups. Moreover, the result showed that the level of Metrnl is inversely correlated with body mass index (BMI) in the controls and the patients. Metrnl levels are also inversely associated with IL-6, and TNF-α in both of the patient groups.
CONCLUSIONS
CONCLUSIONS
The current study is the first one reporting the decreased levels of Metrnl in serum among patients with IBD, which is inversely related with BMI, TNF-α, and IL-6. These results suggested a possible relation of Metrnl with the pathogenesis of IBD, particularly through inflammatory process, although further studies are warranted to dissect the possible mechanism.
Identifiants
pubmed: 33126870
doi: 10.1186/s12944-020-01404-6
pii: 10.1186/s12944-020-01404-6
pmc: PMC7602304
doi:
Substances chimiques
Adipokines
0
IL6 protein, human
0
Interleukin-6
0
Metrnl protein, human
0
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
230Références
Arch Physiol Biochem. 2020 Oct;126(4):335-340
pubmed: 30463448
Med Sci Monit. 2019 Mar 31;25:2337-2343
pubmed: 30928991
PLoS One. 2018 Sep 13;13(9):e0204180
pubmed: 30212581
Diabetes. 2015 Dec;64(12):4011-22
pubmed: 26307585
Biomolecules. 2019 Nov 26;9(12):
pubmed: 31779136
J Crohns Colitis. 2019 Jul 25;13(7):931-941
pubmed: 30615095
Cells. 2019 Oct 19;8(10):
pubmed: 31635130
Front Immunol. 2016 Apr 22;7:154
pubmed: 27148273
Diabetes Res Clin Pract. 2018 Feb;136:100-107
pubmed: 29199003
Gut. 2008 Feb;57(2):205-10
pubmed: 17905821
Clin Immunol. 2019 Nov;208:108253
pubmed: 31470086
Diabetes Res Clin Pract. 2018 Jan;135:7-10
pubmed: 29097285
Horm Mol Biol Clin Investig. 2017 Aug 29;31(2):
pubmed: 28850545
Biomed Res Int. 2017;2017:8201672
pubmed: 28831399
Cytokine. 2019 Jan;113:326-331
pubmed: 30337217
Clin J Gastroenterol. 2020 Apr;13(2):139-152
pubmed: 31452062
Exp Mol Med. 2018 Sep 13;50(9):122
pubmed: 30213948
World J Gastroenterol. 2016 Sep 21;22(35):7868-81
pubmed: 27672284
Saudi J Gastroenterol. 2011 Nov-Dec;17(6):376-82
pubmed: 22064334
JAMA. 2013 May 22;309(20):2150-8
pubmed: 23695484
Front Immunol. 2018 Oct 12;9:1974
pubmed: 30369924
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110-121
pubmed: 27899815
Inflamm Bowel Dis. 2014 Dec;20(12):2483-92
pubmed: 25185685
Acta Pharmacol Sin. 2016 Nov;37(11):1458-1466
pubmed: 27546006
Nutrients. 2018 Sep 01;10(9):
pubmed: 30200405